Clinical Trial Update: Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update describes Zanzalintinib for metastatic clear cell renal cell carcinoma with bone metastases, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Zanzalintinib (Zanzalintinib)

Snippet

Sponsor: Kelly Fitzgerald, MD | Conditions: Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING